Feed

Glioblastoma is the most common and aggressive malignant brain tumor, characterized by poor response to current therapies and inevitable recurrence. Novel therapeutic strategies are urgently needed. Lansbermin-I, a disintegrin isolated from the venom of Porthidium lansbergii lansbergii, was purified, sequenced, structurally modeled, and evaluated for its antitumor potential against the human Glioblastoma cell line T98G. Cytotoxicity assays revealed a dose-dependent effect, with Lansbermin-I inducing up to 38.1% cell death at 100 μg/mL, surpassing the activity of temozolomide (34.9%) while exhibiting lower toxicity on non-tumorigenic human astrocytes (28% vs. 37%). Lansbermin-I also inhibited T98G adhesion to fibronectin by nearly 80% (p < 0.0001), suggesting interference with integrin-mediated interactions. Flow cytometry demonstrated a significant increase in apoptotic cells (60% vs. 36% in control) and cell cycle arrest at the G1 phase. In silico docking studies supported a strong interaction of Lansbermin-I with integrin αvβ3, comparable to that of fibronectin, reinforcing its potential mechanism of action through the disruption of adhesion and survival signaling. Collectively, these findings highlight Lansbermin-I as a promising selective prototype for Glioblastoma therapy. Further studies are warranted to elucidate its molecular targets and evaluate its efficacy in preclinical models.